Key Points Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, including several patent cliffs. New launches, pipeline progress, and a dividend program still make it attractive. 10 stocks we like better than Bristol Myers Squibb › The past five years have been challenging for Bristol Myers Squibb (NYSE: BMY). The company lost patent exclusivity for some key products, including one that was once its best-selling medicine, can ...